SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The S&P 500 is facing intense volatility as the market struggles with tech-sector rotation, concerns over semiconductor valuations, and geopolitical tensions. Community sentiment is deeply divided, with many traders debating whether recent price action signifies a healthy consolidation or the early stages of a broader market correction.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp (SNDK) is witnessing a parabolic rally driven by an AI-induced memory supercycle and persistent NAND supply shortages that investors believe will last for years. While the stock has reached extreme valuations, the community remains sharply divided between bulls chasing the intense momentum and bears anticipating a massive rug pull due to the lack of significant pullbacks.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing intense investor focus as it nears earnings, driven by a surge in demand for AI-critical memory and a strategic infrastructure agreement with Anthropic. The community is actively debating whether the stock's massive rally is a sustainable re-rating based on structural AI demand or an overextended bubble primed for a post-earnings pullback.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is trending as investors react to two White House executive orders designed to accelerate national quantum computing and sensing capabilities, a move the community views as a major validation of the company's strategic alignment with U.S. defense interests. While many participants are actively discussing the potential for a long-term rally and upcoming corporate milestones, some traders remain cautious, highlighting the high volatility and current market pressure impacting the share price.

Roundhill ETF Trust - Roundhill Memory ETF

Roundhill Memory ETF ($DRAM) is trending as investors aggressively position into memory and storage infrastructure, viewing it as a critical bottleneck for AI scaling rather than a typical cyclical semiconductor play. The community is focused on the sector's long-term supply constraints and pricing power, with many traders actively accumulating positions in anticipation of upcoming major earnings reports and potential structural re-ratings within the broader AI supply chain.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as traders closely watch a divergence between semiconductor strength and significant volatility in other major tech names, alongside concerns regarding liquidity and geopolitical risks. The community is actively debating whether current price action signals a healthy rotation or a deeper structural correction as market participants navigate overnight volatility and uncertain macroeconomic signals.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is facing intense downward pressure following its recent IPO as investors grapple with high valuations, aggressive cash-burning AI initiatives, and fears of significant share dilution upon the expiration of lockup periods. The community remains deeply divided, with vocal bears labeling the stock an overhyped retail trap, while long-term bulls defend the company's visionary growth potential and institutional backing.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is seeing heightened investor activity as the market anticipates key maintenance study data later this year, with ongoing debates centering on the company's potential to remain independent versus being a prime acquisition target. Community sentiment remains polarized between long-term holders betting on the disruptive potential of VK2735 and skeptics wary of dilution risks and the management's strategic pace in a rapidly evolving obesity market.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

The iShares Semiconductor ETF (SOXX) is currently the focal point of a heated debate between retail traders who view the sector as a disconnected AI bubble and those aggressively buying the dip on the belief that secular growth remains intact. Community sentiment is deeply polarized, with many investors pointing to excessive valuations and broader macro risks, while bulls ignore these concerns, pointing to persistent institutional buying and record-breaking inflows despite broader market volatility.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending following the failure of its Phase 3 SigVig-002 trial for sigvotatug vedotin, a significant setback for the company's oncology pipeline that has investors questioning its growth strategy and leadership. The community is actively debating the future of Pfizer's oncology investments, the impact of recent leadership transitions, and whether the stock's dividend yield justifies holding through the ongoing clinical and structural uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's  What You Should Know

The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 155.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here's Why You Should Add JANX Stock to Your Portfolio Now

Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates, new studies and expanded partnerships with BMY and MRK.

Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates

Janux Therapeutics (JANX) delivered earnings and revenue surprises of +21.83% and -75.11%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter...

How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%

The consensus price target hints at an 180.4% upside potential for Janux Therapeutics (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Janux Therapeutics (NASDAQ:JANX) Upgraded by Truist Financial to Strong-Buy Rating

Truist Financial upgraded Janux Therapeutics to a "strong-buy" rating in a research report on Monday...

JonesTrading Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price

JonesTrading cut their price target on shares of Janux Therapeutics from $50.00 to $28.00 and set a "buy" rating on the stock in a report on Tuesday...

JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline

Equity

The company said that it came to the decision after completing early-stage trials across multiple solid tumor indications and an internal review of the data.

Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it will discontinue further...

Will Acute Care Strength Help Universal Health Offset Q1 Rising Costs?

UHS heads into Q1 earnings with acute care and behavioral health growth, but rising labor and supply costs could cloud the outlook.

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.

Janux Therapeutics Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

JANXJanux Therapeutics Inc

Fundamentals

Latest JANX News